BIOCERES INC CROP BUSINESS
& BIOCERES SEMILLAS S.A.

Unaudited interim condensed combined financial statements as of September 30, 2018, June 30, 2018 and for the three-month periods ended September 30, 2018 and 2017

INDEX

Unaudited interim condensed combined financial statements as of September 30, 2018, June 30, 2018 and for the three-month periods ended September 30, 2018 and 2017.

BIOCERES INC CROP BUSINESS & BIOCERES SEMILLAS S.A.

UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF FINANCIAL POSITION
As of September 30, 2018 and June 30, 2018
(Amounts in USD)

	Notes	09/30/2018	06/30/2018
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	5.1	3,255,981	2,215,103
Other financial assets	5.2	4,562,725	4,550,847
Trade receivables	5.3	52,806,907	52,888,427
Other receivables	5.4	4,982,346	4,240,205
Income and minimum presumed income taxes recoverable		1,476,193	2,082,269
Inventories	5.5	25,089,935	19,366,001
Total current assets		92,174,087	85,342,852
NON-CURRENT ASSETS			
Other financial assets	5.2	284,683	243,358
Other receivables	5.4	4,899,666	4,979,507
Income and minimum presumed income taxes recoverable		521,037	126,653
Deferred tax assets		597,522	5,601,821
Investments in joint ventures	9	22,509,645	19,072,055
Property, plant and equipment	5.6	37,441,647	40,177,146
Intangible assets	5.7	29,873,603	26,657,345
Goodwill	5.8	17,838,269	14,438,027
Total non-current assets		113,966,072	111,295,912
Total assets		206,140,159	196,638,764

The accompanying Notes are an integral part of these Unaudited interim condensed combined financial statements. Related parties balances and transactions are disclosed in Note 12.

BIOCERES INC CROP BUSINESS & BIOCERES SEMILLAS S.A.

UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF FINANCIAL POSITION

As of September 30, 2018 and June 30, 2018
(Amounts in USD)

LIABILITIES	Notes	09/30/2018	06/30/2018
CURRENT LIABILITIES			
Trade and other payables	5.9	37,881,886	27,708,830
Borrowings	5.10	71,235,483	65,308,928
Employee benefits and social security	5.11	4,210,621	4,411,713
Deferred revenue and advances from customers	5.12	2,831,527	1,007,301
Income and minimum presumed income taxes payable		579	2,569
Government grants	5.13	6,257	17,695
Financed payment - Acquisition of business	5.16	20,616,463	20,223,590
Total current liabilities		136,782,816	118,680,626
NON-CURRENT LIABILITIES			
Borrowings	5.10	21,703,744	25,708,205
Government grants	5.13	10,871	15,532
Investments in joint ventures	9	2,086,376	2,012,298
Deferred tax liabilities		9,807,855	13,591,942
Provisions	5.14	458,874	845,486
Financed payment - Acquisition of business	5.16	2,702,519	2,651,019
Total non-current liabilities		36,770,239	44,824,482
Total liabilities		173,553,055	163,505,108
EQUITY			
Equity attributable to owners of the parent		11,116,962	13,713,484
Non-controlling interests		21,470,142	19,420,172
Total equity		32,587,104	33,133,656
Total equity and liabilities		206,140,159	196,638,764

The accompanying Notes are an integral part of these Unaudited interim condensed combined financial statements. Related parties balances and transactions are disclosed in Note 12.

BIOCERES INC CROP BUSINESS & BIOCERES SEMILLAS S.A.

UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE INCOME

For the three-month periods ended September 30, 2018 and 2017

(Amounts in USD)

	Notes	09/30/2018	09/30/2017
Revenue	6.1	29,605,745	33,859,549
Government grants	5.13	6,479	14,612
Total revenue		**29,612,224**	**33,874,161**
Cost of sales	6.2	(14,499,010)	(20,011,633)
Research and development expenses	6.3	(1,048,492)	(938,374)
Selling, general and administrative expenses	6.4	(6,080,485)	(8,395,208)
Share of income of joint ventures	9	80,156	55,117
Other income or expenses, net		101,611	(56,878)
Operating profit		**8,166,004**	**4,527,185**
Finance income	6.5	12,464,317	1,326,714
Finance costs	6.6	(26,199,971)	(6,766,835)
Loss before income tax		**(5,569,650)**	**(912,936)**
Income tax		1,970,393	289,837
Loss for the period		**(3,599,257)**	**(623,099)**
Other comprehensive income or loss		**(16,395,253)**	**(4,156,488)**
Items that may be subsequently reclassified to profit and loss		***(19,211,348)***	***(4,156,488)***
Exchange differences on translation of foreign operations from joint ventures		(5,734,527)	(1,264,283)
Exchange differences on translation of foreign operations		(13,476,821)	(2,892,205)
Items that will not be subsequently reclassified to loss and profit		***2,816,095***	**-**
Revaluation of property,plant and equipment, net of tax, of JV and associates		562,268	-
Revaluation of property, plant and equipment, net of tax		2,253,827	-
Total comprehensive loss		**(19,994,510)**	**(4,779,587)**
Loss for the period attributable to:			
Equity holders of the parent		(2,618,445)	(826,318)
Non-controlling interests		(980,812)	203,219
		(3,599,257)	(623,099)
Total comprehensive income/loss attributable to:			
Equity holders of the parent		(14,247,185)	(3,739,593)
Non-controlling interests		(5,747,325)	(1,039,994)
		(19,994,510)	(4,779,587)

The accompanying Notes are an integral part of these Unaudited interim condensed combined financial statements. Related party balances and transactions are disclosed in Note 12.

BIOCERES INC & BIOCERES SEMILLAS S.A.

UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended September 30, 2018 and 2017

(Amounts in USD)

Description	Attributable to the equity holders of the parent						Non-controlling Interests	Total equity
	Parent company investment (Note 9.1)	Stock options	Retained deficit	Foreign currency translation reserve	Revaluation of PP&E	Equity / (deficit) attributable to owners of the parent		
06/30/2017	56,257,329	72,822	(15,110,050)	(6,598,080)	1,219,600	35,841,621	41,397,445	77,239,066
Stock options	-	10,540	-	-	-	10,540		10,540
Loss for the period	-	-	(826,318)	-	-	(826,318)	203,219	(623,099)
Other comprehensive loss	-	-	-	(2,913,275)	-	(2,913,275)	(1,243,213)	(4,156,488)
09/30/2017	56,257,329	83,362	(15,936,368)	(9,511,355)	1,219,600	32,112,568	40,357,451	72,470,019

Description	Attributable to the equity holders of the parent						Non-controlling Interests	Total equity
	Parent company investment (Note 9.1)	Stock options	Retained deficit	Foreign currency translation reserve	Revaluation of PP&E	Equity / (deficit) attributable to owners of the parent		
06/30/2018	68,026,259	102,827	(26,149,583)	(36,612,070)	8,346,051	13,713,484	19,420,172	33,133,656
Adjustament of opening balance for the application of IAS 29	-	-	19,560,024	-	-	19,560,024	7,797,295	27,357,319
Parent company investment	(7,913,165)	-	-	-	-	(7,913,165)	-	(7,913,165)
Stock options	-	3,804	-	-	-	3,804	-	3,804
Loss for the period	-	-	(2,618,445)	-	-	(2,618,445)	(980,812)	(3,599,257)
Other comprehensive income	-	-	-	(15,571,273)	3,942,533	(11,628,740)	(4,766,513)	(16,395,253)
09/30/2018	60,113,094	106,631	(9,208,004)	(52,183,343)	12,288,584	11,116,962	21,470,142	32,587,104

The accompanying Notes are an integral part of these Unaudited interim condensed combined financial statements. Related parties balances and transactions are disclosed in Note 12

BIOCERES INC CROP BUSINESS & BIOCERES SEMILLAS S.A.

UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF CASH FLOWS
For the three-month periods ended September 30, 2018 and 2017

(Amounts in USD)

	Notes	09/30/2018	09/30/2017
OPERATING ACTIVITIES			
Loss for the period		(3,599,257)	(623,099)
Adjustments to reconcile loss to net cash flows			
Income tax		(1,970,393)	(289,837)
Depreciation of property, plant and equipment	5.6	404,284	634,431
Amortization of intangible assets	5.7	417,871	577,033
Share of income of joint ventures	9	(80,156)	(55,117)
Changes in fair value of financial assets		(29,349)	(47,680)
Provisions for contingencies	5.16	(5,047)	-
Allowance for impairment of trade debtors	5.16	(9,067)	381,551
Allowance for obsolescence	5.16	213,534	19,923
Stock option		3,804	10,540
Gain or loss on sale of equipment and intangible assets		12,552	425,327
Interests and exchange differences from borrowings		598,381	(2,991,704)
Other financial results accrued		(1,639,347)	(21,644)
Working capital adjustments			
Trade receivables		90,587	(16,297,522)
Other receivables		(662,300)	2,314,520
Income and minimum presumed income taxes		209,702	1,416,245
Inventories		(5,937,468)	(5,155,807)
Trade and other payables		10,045,240	13,239,243
Employee benefits and social security		(201,092)	350,431
Deferred revenue and advances from customers		1,824,226	1,310,369
Income and minimum presumed income taxes payable		-	(863,169)
Government grants		(16,099)	(19,278)
Net cash flows used in operating activities		**(329,394)**	**(5,685,244)**

The accompanying Notes are an integral part of these Unaudited interim condensed combined financial statements. Related parties balances and transactions are disclosed in Note 12.

UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF CASH FLOWS
For the three-month periods ended September 30, 2018 and 2017

(Amounts in USD)

	Notes	09/30/2018	09/30/2017
INVESTMENT ACTIVITIES			
Purchase of property, plant and equipment	5.6	(114,063)	(303,225)
Loans granted to joint ventures		-	(2,059,818)
Capitalized development expenditures	5.7	(283,752)	(111,124)
Purchase of intangible assets	5.7	-	(236)
Net cash flows used in investing activities		**(397,815)**	**(2,474,403)**
FINANCING ACTIVITIES			
Proceeds from borrowings		16,101,533	72,737,914
Repayment of borrowings and interest payments		(13,158,772)	(65,108,984)
(Decrease)/Increase bank overdraft and other short-term borrowings		(1,174,674)	296,282
Net cash flows provided by financing activities		**1,768,087**	**7,925,212**
Net increase / (decrease) in cash and cash equivalents		**1,040,878**	**(234,435)**
Cash and cash equivalents as of beginning of the period	5.1	**2,215,103**	**1,679,478**
Cash and cash equivalents as of the end of the period	5.1	**3,255,981**	**1,445,043**

The accompanying Notes are an integral part of these Unaudited interim condensed combined financial statements. Related parties balances and transactions are disclosed in Note 12.

Index

1. GENERAL INFORMATION

These Combined financial statements are comprised by Bioceres Inc Crop Business, using a carve-out basis ("Bioceres Inc Crop Business") and Bioceres Semillas S.A. ("Bioceres Semillas" and together with Bioceres Inc Crop Business, the "Group").

BCS Holdings, Inc ("BCS Holdings") will be a US domiciled holding company that will be created prior to the consummation of the business combination with Union Acquisition Corp. ("Union"), a Cayman Islands exempted special purpose acquisition company listed on the New York Stock Exchange and Domestic filer for SEC purposes. BCS Holdings will receive from Bioceres Inc certain assets and liabilities prior to the consummation of the business combination. Bioceres Inc Crop Business, through the newly created holding intermediate BCS Holdings, and Bioceres Semillas will be acquired by Union in the business combination.

The Group is a fully-integrated agricultural biotechnology business with a leadership position in the South America region. It operates multiple technology platforms to develop and commercialize products that enhance crop productivity and expand feedstock applications in order to provide value to its customers around the world. The Group is ultimately controlled by Bioceres S.A., domiciled in the City of Rosario, Province of Santa Fe, Argentina.

See the details of the business combination in the Combined financial statements as of June 30, 2018, June 30, 2017, December 31, 2016, for the year ended June 30, 2018, for the six-month transition period ended June 30, 2017 and for the years ended December 31, 2016 and 2015.

Financial and economic situation

Upon completion of the business combination with Union, the newly created BCS Holdings will have access to funds released from Union´s Trust Account after payment of any shares redemptions that could occur.

With net proceeds form the business combination the newly created BCS Holdings intends to meet current financial obligations arising from the acquisition of Rizobacter. These financial obligations are represented by outstanding deferred payments to sellers of Rizobacter, as well as current borrowings obtained by the Group in the past and used to pay installments of the acquisition as they became due (Note 5.15). Furthermore, remaining net proceeds from the business combination with Union after payment of acquisition related obligations, will be destined to working capital requirements enabling the Group to optimize its capital structure and financing costs.

To meet short-term debts, the Group could, if necessary, issue a new Corporate Bond up to US$40 million. This program is already authorized by the regulatory authorities of Argentina and could be allocated to the Group's needs (Note 5.15). In addition, the Group has revolving credit facilities up to an amount of USD 31.1million with financial institutions, that jointly with the generation of resources from the business operations, allows the Group to meet its current financial obligations.

2. ACCOUNTING STANDARDS AND BASIS OF PREPARATION

2.1. Statement of compliance with IFRS as issued by IASB

These unaudited interim condensed combined financial statements for the three-months period ended September 30, 2018 has been prepared in accordance with Accounting Standard IAS 34 Interim Financial Reporting.

These unaudited interim condensed combined financial statements does not include all the notes of the type normally included in an annual Financial Statements. Accordingly, these unaudited interim condensed combined financial statements is to be read in conjunction with the Combined financial statements as of June 30, 2018.

2.2. <u>Scope of combination</u>

IFRS provides no guidelines for the preparation of combined financial statements, which are therefore subject to the rules given in International Accounting Standards (IAS) 8.12. This paragraph requires consideration of the most recent pronouncements of other standard-setting bodies, other financial reporting requirements and recognized industry practices. During the reporting periods of the Unaudited Interim condensed combined financial statements, the assets and liabilities forming the Group were under common control of Bioceres.

2.3. <u>Authorization for the issue of the Unaudited Interim condensed combined financial statements</u>

These Unaudited Interim condensed combined financial statements of the Group as of September 30, 2018, June 30, 2018 and for the three-month period ended September 30, 2018 and 2017 have been authorized by the Board of Directors of Bioceres S.A. at their meetings held on December 21, 2018.

2.4. <u>Basis of measurement</u>

The Unaudited Interim condensed combined financial statements of the Group have been prepared using:

- Going Concern Basis of Accounting, considering the conclusion of the assessment made by the Group's Management about the ability of the Group and its subsidiaries to continue as a going concern, in accordance with the requirements of paragraph 25 of IAS 1, "Presentation of Financial Statements".

- Accrual Basis of Accounting (except for cash flows information). Under this basis of accounting, the effects of transactions and other events are recognized as they occur, even when there are no cash flows.

2.5. <u>Functional currency and presentation currency</u>

a) Functional currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic market in which the entity operates (i.e., "the functional currency").

IAS 29 "Financial reporting in hyperinflationary economies" requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy with high inflation, whether they are based on the historical cost method or the current cost method, be stated in terms of the measuring unit current at the closing date of the reporting period. For such purpose, the inflation produced from the acquisition date or the revaluation date, as applicable, must be computed in non-monetary items. The standard details a series of factors to be considered for concluding whether an economy is a hyperinflationary economy, including, but not limited to, a cumulative inflation rate over a three-year period that approaches or exceeds 100%. Inflation accumulated in three years, as of June 30, 2018, is over 100%. It is for this reason that, in accordance with IAS 29, the Argentine economy should be considered as high inflation since July 1, 2018. Consequently, the Group has applied IAS 29 to these financial statements.

In an inflationary period, any entity that maintains an excess of monetary assets over monetary liabilities, will lose purchasing power, and any entity that maintains an excess of monetary liabilities on monetary assets, will gain purchasing power, provided that such items are not subject to an adjustment mechanism.

Briefly, the restatement mechanism of IAS 29 establishes that monetary assets and liabilities will not be restated because they are already expressed in a current unit of measurement at the end of the reporting period. Assets and liabilities subject to adjustments based on specific agreements, will be adjusted according to that agreements. Non-monetary items measured at their current values at the end of the reporting period, such as the net realizable value or others, do not need to be restated. The remaining non-monetary assets and liabilities will be restated for a general price index. The loss or gain for the net monetary position will be included in the net result of the reporting period, revealing this information in a separate line item.

The inflation adjustment on the initial balances was calculated by means of conversion factor derived from the Argentine price indexes published by the National Institute of Statistics. The average index for the three-month period ended September 30, 2018, was 1.141.

The comparative figures in these Unaudited Interim condensed combined financial statements presented in a stable currency are not adjusted for subsequent changes in the price level or exchange rates. This resulted in an initial difference, arising on the adoption of hyperinflation accounting, between the closing equity of the previous year and the opening equity of the current year. The Company recognized this initial difference directly in equity.

b) Presentation currency

The Unaudited Interim condensed combined financial statements of the Group are presented in USD, which is the presentation currency.

c) Foreign currency

Transactions entered into by Group entities in a currency other than their functional currency are recorded at the relevant exchange rates as of the date upon which such transactions occur. Foreign currency monetary assets and liabilities are translated at the prevailing exchanges rates as of the final day of each reporting period. Exchange differences arising on the retranslation of unsettled monetary assets and liabilities are recognized immediately in profit or loss, except for foreign currency borrowings qualifying as a hedge of a net investment in a foreign operation for which exchange differences are recognized in other comprehensive income and accumulated in the foreign exchange reserve along with the exchange differences arising on the retranslation of the foreign operation. Upon the disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to such operation up to the date of disposal are transferred to the Combined statement of profit or loss and other comprehensive income as part of the profit or loss taking place upon such disposal.

2.6. Changes in accounting policies

The accounting policies adopted in the preparation of the Unaudited Interim condensed financial statements are consistent with those adopted for the preparation of the Anuual combined financial statements.

2.7. Changes in accounting estimates and judgments

There were no significant changes in accounting estimates and judgments with respect to the Combined financial statements as of June 30, 2018, June 30, 2017, December 31, 2016, for the year ended June 30, 2018, for the six-month transition period ended June 30, 2017 and for the years ended December 31, 2016 and 2015.

2.8. Changes in subsidiaries

At the end of the period ended September 30, 2018, the participation of Rizobacter S.A. in Indrasa S.A. decreased by 35%, therefore the Group loss the control over this subsidiary.

3. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB

The follwing new standards became applicable for the current reporting period and the Group had to change its accounting policies as a result of adopting the following standards:

-IFRS 15 Revenue from Contracts with Custumers

The main changes are the following:

The standard introduces a new five-step model for recognizing revenue from contracts with customers:

1) Identifying the contract with the customer.

2) Identifying separate performance obligations in the contract.

3) Determining the transaction price.

4) Allocating the transaction price to separate performance obligations.

5) Recognizing revenue when the performance obligations are satisfied.

The Group has chosen a modified retrospective application of IFRS 15.

The impact of adopting IFRS 15 was not significant and therefore no cumulative effect upon adoption was recorded.

The standars and interpretations issued, but not yet in force at the date of issuance of these Unaudited Interim condensed combined financial statements, which are or may be applicable to the Group, are:

IFRS 16 – Leases.

IFRIC 23: Uncertainty over income tax treatments

The Group intends to adopt these standards and interpretations when they enter into force, except that the opposite is indicated.

IFRS 16 - Leases

IFRS 16 was issued in January 2016. It will result in almost all leases being recognized on the balance sheet, as the distinction between operating and finance leases will be removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognized. The only exceptions are short-term and low-value leases.

The accounting for lessors will not significantly change.

The standard will affect primarily the accounting for the Group’s operating leases. However, the Group has not yet assessed what adjustments, if any, are necessary due to the change in the definition of the lease term and the different treatment of variable lease payments and of extension and termination options. It is therefore not yet possible to estimate the amount of right-of-use assets and lease liabilities that will have to be recognized on adoption of the new standard and how this may affect the Group’s profit or loss and classification of cash flows going forward.

The new standard will be effective for financial years commencing on or after January 1, 2019. At this stage, the Group does not intend to adopt the standard before its effective date.

The Group is currently assessing the impact of the new disclosure requirements and currently it is not possible to estimate the potential effects to the Group.

IFRIC 23: Uncertainty over income tax treatments

On 7 June 2017, the IFRS Interpretations Committee (IFRS IC) issued IFRIC 23, which clarifies how the recognition and measurement requirements of IAS 12 Income taxes are applied where there is uncertainty over income tax treatments.

The interpretation specifically addresses: i) whether an entity considers uncertain tax treatments separately, ii) the assumptions an entity makes about the examination of tax treatments by taxation authorities, iii) how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and iv) how an entity considers changes in facts and circumstances

IFRIC 23 is effective for annual periods beginning on or after 1 January 2019. At this stage, the Group does not intend to adopt the standard before its effective date. The Group does not expect impacts due to the application of this interpretation.

4. SEASONALITY

The Group revenues fluctuate depending on the timing of orders from our distributors and customers and on prevailing seed market prices, which influence the purchase decisions of growers, the end users of seed and integrated products, crop protection products and crop nutrition products. Given the cyclicality of crop planting and harvesting and South America's planting and growing seasons, which vary from year to year, our business is highly seasonal. This results in substantial fluctuations in quarterly sales and profitability. Generally, the Group sales are concentrated in the third and fourth quarters of each calendar year, when demand for seed and integrated products, crop protection products and crop nutrition products increases as growers begin planting their fields. With seed and integrated products business, the Group contract with growers and seed suppliers based upon our anticipated market demand. Generally, in seed and integrated products business we stock the seed during the harvest season and ship from inventory throughout the year, with the objective of selling most of the inventory from the current year's harvest before the next year's, with crop protection and crop nutrition business following a similar cycle to the seed cycle. The impact of seasonality and the resulting fluctuations in quarterly results may be moderated as we achieve our international expansion plans for seed business in geographies with contrasting seasons and climates.

5. INFORMATION ABOUT COMPONENTS OF UNAUDITED INTERIM CONDENSED COMBINED STATEMENTS OF FINANCIAL POSITION

5.1. Cash and cash equivalents

	09/30/2018	06/30/2018
Cash and banks	3,255,981	2,215,103
	3,255,981	2,215,103

5.2. Other financial assets

	09/30/2018	06/30/2018
Current		
Other marketable securities	8,766	12,526
Restricted short-term deposit	4,553,959	4,538,321
	4,562,725	4,550,847

	09/30/2018	06/30/2018
Non-current		
Shares of Bioceres S.A.	282,977	240,920
Other marketable securities	1,706	2,438
	284,683	243,358

5.3. Trade receivables

	09/30/2018	06/30/2018
Trade debtors	39,761,550	44,641,053
Allowance for impairment of trade debtors	(2,655,975)	(3,212,170)
Shareholders and other related parties (Note 12)	940,126	571,216
Allowance for impairment of related parties (Note 12)	(22,246)	(23,126)
Allowance for return of goods	(415,987)	(1,517,361)
Trade debtors - Parent company (Note 12)	401,017	361,606
Trade debtors - Joint ventures (Note 12)	174,441	209,039
Discounted and deferred checks	14,623,981	11,858,170
	52,806,907	52,888,427

Variations in the allowance for uncollectible trade receivables are reported in Note 5.16.

5.4. Other receivables

	09/30/2018	06/30/2018
Current		
Taxes	891,983	664,926
Insurance to be accrued	7,699	9,219
Other receivables - Shareholders and other related parties (Note 12)	3,656	119,677
Other receivables - Parent Company (Note 12)	322,475	103,251
Other receivables - Joint ventures (Note 12)	1,732,782	1,962,459
Prepayments to suppliers	1,411,969	516,742
Reimbursements over exports	362,563	362,815
Loans receivable	-	1,360
Miscellaneous	249,219	499,756
	4,982,346	4,240,205

	09/30/2018	06/30/2018
Non-Current		
Taxes	115,983	295,924
Reimbursements over exports	547,771	346,575
Other receivables - Joint ventures (Note 12)	4,235,912	4,337,008
	4,899,666	4,979,507

5.5. Inventories

	09/30/2018	06/30/2018
Agrochemicals	15,666	94,486
Seeds and grains	842,468	514,000
Microbiological resale products	12,531,586	8,389,191
Microbiological products produced	6,573,530	6,383,263
Goods in transit	2,564,976	776,869
Supplies	3,409,033	3,978,934
Allowance for obsolescence	(847,324)	(770,742)
	25,089,935	19,366,001

The roll-forward of allowance for obsolescence is in Note 5.16.

5.6. Property, plant and equipment

Property, plant and equipment as of September 30, 2018 and June 30, 2018 included the following:

	09/30/2018	06/30/2018
Gross carrying amount	42,834,109	44,764,394
Accumulated depreciation	(5,392,462)	(4,587,248)
Net carrying amount	37,441,647	40,177,146

1. Net carrying amount for each class of assets is as follows:

Class	Net carrying amount 09/30/2018	Net carrying amount 06/30/2018
Office equipment	174,591	194,819
Vehicles	1,053,083	1,099,603
Equipment and computer software	144,636	212,236
Fixtures and fittings	3,473,264	3,508,083
Machinery and equipment	4,985,386	4,466,293
Land and buildings	27,372,483	30,513,273
Buildings in progress	238,204	182,839
Total	37,441,647	40,177,146

2. Gross carrying amount as of September 30, 2018 is as follows:

Class	Gross carrying amount						
	As of the beginning of period	Adjustement of opening net book amount for application of IAS 29	Additions	Disposals	Foreign currency translation	Revaluation	As of the end of period
Office equipment	243,948	194,944	11,713	(6,605)	(162,867)	-	281,133
Vehicles	1,660,294	623,032	20,893	-	(556,330)	-	1,747,889
Equipment and computer software	419,638	299,670	7,692	-	(238,075)	-	488,925
Fixtures and fittings	3,826,665	1,777,746	-	-	(1,513,426)	-	4,090,985
Machinery and equipment	5,404,029	3,303,509	33,146	(18,643)	(2,333,061)	-	6,388,980
Land and buildings	33,026,981	3,356,144	-	-	(10,199,207)	3,414,075	29,597,993
Buildings in progress	182,839	96,409	40,619	-	(81,663)	-	238,204
Total	44,764,394	9,651,454	114,063	(25,248)	(15,084,629)	3,414,075	42,834,109

3. Accumulated depreciation as of September 30, 2018 is as follows:

Class	Depreciation						
	Accumulated as of the beginning of period	Adjustement of opening net book amount for application of IAS 29	Disposals	Of the period	Foreign currency translation	Revaluation	Accumulated as of the end of period
Office equipment	49,129	155,774	(3,116)	6,630	(101,875)	-	106,542
Vehicles	560,691	293,553	-	83,682	(243,120)	-	694,806
Equipment and computer software	207,402	300,560	-	11,391	(175,064)	-	344,289
Fixtures and fittings	318,582	506,331	-	68,107	(275,299)	-	617,721
Machinery and equipment	937,736	1,178,567	(9,580)	125,981	(829,110)	-	1,403,594
Land and buildings	2,513,708	392,419	-	108,493	(1,192,222)	403,112	2,225,510
Total	4,587,248	2,827,204	(12,696)	404,284	(2,816,690)	403,112	5,392,462

4. Gross carrying amount as of September 30, 2017 is as follows:

Class	Gross carrying amount					
	As of the beginning of period	Additions	Transfers	Disposals	Foreign currency translation	As of the end of period
Office equipment	252,220	4,133	-	(4,812)	(6,614)	244,927
Vehicles	2,223,102	108,123	-	(82,974)	(58,940)	2,189,311
Equipment and computer software	426,530	9,718	3,812	-	(13,074)	426,986
Fixtures and fittings	4,665,074	282	188,163	-	(182,786)	4,670,733
Machinery and equipment	9,177,077	52,293	-	(26,061)	(381,022)	8,822,287
Land and buildings	30,931,226	50,798	94,755	-	(1,201,029)	29,875,750
Buildings in progress	870,469	77,878	(286,730)	(46,240)	(27,362)	588,015
Total	48,545,698	303,225	-	(160,087)	(1,870,827)	46,818,009

5. Accumulated depreciation as of September 30, 2017 is as follows:

Class	Depreciation				
	Accumulated as of the beginning of period	Disposals	Of the period	Foreign currency translation	Accumulated as of the end of period
Office equipment	31,522	-	8,103	(810)	38,815
Vehicles	373,216	(37,985)	188,085	(7,075)	516,241
Equipment and computer software	118,169	-	33,972	(1,771)	150,370
Fixtures and fittings	204,171	-	62,969	(7,815)	259,325
Machinery and equipment	771,636	-	197,335	(52,809)	916,162
Land and buildings	828,109	-	143,967	(31,897)	940,179
Total	2,326,823	(37,985)	634,431	(102,177)	2,821,092

The depreciation charge is included in Notes 6.3 and 6.4.

Revaluation of property, plant and equipment

At a minimum, the Group updates their assessment of the fair value of its land and buildings at the end of each reporting year (after the revaluation policy was adopted), taking into account the most recent independent valuations and market data. Valuations were performed at September 30, 2018. Management determined the property, plant and equipment's value within a range of reasonable fair value estimates.

All resulting fair value estimates for properties are included in level 3.

5.7. Intangible assets

Intangible assets as of September 30, 2018 and June 30, 2018 included the following:

	09/30/2018	06/30/2018
Gross carrying amount	33,235,633	29,155,315
Accumulated amortization	(3,362,030)	(2,497,970)
Net carrying amount	29,873,603	26,657,345

1. Net carrying amount of each class of intangible assets is as follows:

Class	Net carrying amount 09/30/2018	Net Carrying amount 06/30/2018
Seed and integrated products		
Soybean HB4	5,158,705	4,927,853
Crop nutrition		
Microbiology products	1,550,407	2,122,484
Other intangible assets		
Trademarks and patents	6,447,979	5,574,682
Software	1,456,259	949,310
Customer loyalty	15,260,253	13,083,016
Total	29,873,603	26,657,345

2. Gross carrying amount as of September 30, 2018 is as follows:

Class	Gross carrying amount					
	As of the beginning of period	Adjustement of opening net book amount for application of IAS 29	Additions	Disposals	Foreign currency translation	As of the end of period
Seed and integrated products						
Soybean HB4	4,927,853	-	230,852	-	-	5,158,705
Crop nutrition						
Microbiology products	2,505,864	192,658	52,900	-	(668,350)	2,083,072
Other intangible assets						
Trademarks and patents	6,278,706	3,005,387	-	-	(1,884,375)	7,399,718
Software	1,444,603	1,484,407	-	-	(832,444)	2,096,566
Customer loyalty	13,998,289	6,700,470	-	-	(4,201,187)	16,497,572
Total	29,155,315	11,382,922	283,752	-	(7,586,356)	33,235,633

3. Accumulated amortization as of September 30, 2018 is as follows:

Class	Amortization					
	Accumulated as of beginning of period	Adjustement of opening net book amount for application of IAS 29	Disposals	Of the period	Foreign currency translation	Accumulated as of the end of period
Crop nutrition						
Microbiology products	383,380	245,725	-	64,518	(160,958)	532,665
Other intangible assets						
Trademarks and patents	704,024	336,989	-	122,018	(211,292)	951,739
Software	495,293	278,679	-	72,705	(206,370)	640,307
Customer loyalty	915,273	438,107	-	158,630	(274,691)	1,237,319
Total	2,497,970	1,299,500	-	417,871	(853,311)	3,362,030

4. Gross carrying amount as of September 30, 2017 is as follows:

Class	Gross carrying amount				
	As of the beginning of period	Additions	Disposals	Foreign currency translation	As of the end of period
Seed and integrated products					
Soybean HB4	3,111,253	-	-	-	3,111,253
Crop nutrition					
Microbiology products	3,782,238	111,124	-	(149,011)	3,744,351
Other intangible assets					
Trademarks and patents	10,906,317	-	-	(429,681)	10,476,636
Software	1,787,925	236	-	(70,439)	1,717,722
Customer loyalty	24,315,484	-	-	(957,968)	23,357,516
Total	43,903,217	111,360	-	(1,607,099)	42,407,478

5. Accumulated amortization as of September 30, 2017 is as follows:

Class	Amortization				
	Accumulated as of beginning of period	Disposals	Of the period	Foreign currency translation	Accumulated as of the end of period
Crop nutrition					
Microbiology products	290,969	-	89,805	(11,217)	369,557
Other intangible assets					
Trademarks and patents	503,553	-	172,282	(19,367)	656,468
Software	395,156	-	90,969	(15,319)	470,806
Customer loyalty	654,648	-	223,977	(25,177)	853,448
Total	1,844,326	-	577,033	(71,080)	2,350,279

The amortization charge is included in Notes 6.3 and 6.4.

5.8. Goodwill

The variations in goodwill occurred during the periods combined correspond to the restatement as a result of inflation adjustment and convertion to presentation currency. There have been no goodwill impairment indicators.

Carrying amount of goodwill as of September 30, 2018 and June 30, 2018 is as follows:

	09/30/2018	06/30/2018
Rizobacter	17,838,269	14,438,027
Total	17,838,269	14,438,027

5.9. Trade and other payables

	09/30/2018	06/30/2018
Trade creditors	28,749,755	22,222,872
Shareholders and other related parties (Note 12)	273,135	365,994
Trade creditors - Joint ventures (Note 12)	7,825,308	3,493,113
Taxes	35,469	35,391
Miscellaneous	998,219	1,591,460
	37,881,886	27,708,830

5.10. Borrowings

	09/30/2018	06/30/2018
Current		
Bank overdraft	171,594	532,912
Bank borrowings	44,885,681	44,061,555
Corporate bonds	-	3,262,924
BAF Loans	11,667,802	5,112,222
Discount checks	9,068,530	10,243,204
Loans payables-Parent company (Note 12)	5,221,697	1,816,084
Finance lease	220,179	280,027
	71,235,483	65,308,928
Non-current		
Bank borrowings	21,403,969	25,253,940
Finance lease	299,775	454,265
	21,703,744	25,708,205

On August 31, 2018, the payment of the last capital and interest service of Corporate bonds were made. After these payments there are no more outstanding Corporate bonds corresponding to the regime of public offering.

The carrying value of some borrowings as of September 30, 2018 measured at amortized cost differ from their fair value. The following fair values measured are based on discounted cash flows (Level 3) due to the use of unobservable inputs, including own credit risk.

	09/30/2018	
	Amortized cost	Fair value
Current		
Bank borrowings	44,885,681	43,523,959
Discount checks	9,068,530	7,518,346
Non-current		
Bank borrowings	21,403,969	17,893,567

The group has met the capital and interest installments whose maturity was effective in the three-month period ended September 30, 2018.

Covenant compliance is required to be measured annually.

5.11. Employee benefits and social security

	09/30/2018	06/30/2018
Salaries and social security	2,312,112	3,146,583
Staff incentives and vacations	1,898,509	1,265,130
	4,210,621	4,411,713

5.12. Deferred revenue and advances from customers

	09/30/2018	06/30/2018
Advances from customers	2,831,527	1,007,301
	2,831,527	1,007,301

5.13. Government grants

	09/30/2018	06/30/2018
Current	6,257	17,695
Non-current	10,871	15,532
Total	17,128	33,227

	09/30/2018	09/30/2017
At of the beginning of the period	33,227	118,545
Received during the period	15,704	29,136
Currency conversion difference	(25,324)	(33,802)
Released to the statement of profit or loss	(6,479)	(14,612)
At the end of period	17,128	99,267

There are neither unfulfilled conditions nor other contingencies attaching to government grants or government assistance.

5.14. Provisions

	09/30/2018	06/30/2018
Provisions for contingencies	458,874	845,486
	458,874	845,486

There are no expected reimbursements related to the provisions.

The roll forward of the provision is in Note 5.16.

5.15. Financed payment – Acquisition of business

	09/30/2018	06/30/2018
Current		
Purchase option	14,889,202	14,605,469
Financed payment to sellers	5,727,261	5,618,121
	20,616,463	20,223,590
Non-current		
Financed payment to sellers	2,702,519	2,651,019
	2,702,519	2,651,019

As of the date of issuance of these Unaudited Interim condensed combined financial statements, the three installments that were due in October 2017, April 2018 and October 2018, have been fully paid for a value of USD 3.5 million, USD 2.9 million and USD 2.9 million, respectively. The funds for this payment was obtained through bank loans.

Purchase option

The Group subscribed to an option to purchase a further 9.99% of Rizobacter for a nominal value of USD 14.9 million. Group Bioceres had the right to exercise this option over a term of two years since October 19, 2016. As from the second anniversary, or if Bioceres S.A. and/or its affiliates purchase a portion or all of the equity interests held by certain shareholders, Group Bioceres will have the obligation to purchase the percentage if the Sellers so require it.

In October, 2018, an addendum to the purchase option was signed with the sellers extending the term of the exercise of the option by Bioceres to March 31, 2019. Additionally, this addendum increases the purchase option to 29.99 % of Rizobacter. The Group would have to pay USD 49.98 million, of which USD 34.995 million (nominal value of the purchase option for the additional 20% of Rizobacter equity interest) are subject to the successful completion of the business combination planed with Union.

The consideration payable will consist in: (i) USD 14,985,000 in cash ("Cash consideration") or/and (ii) USD 34,995,000 in UAC shares redeemed in connection with the business combination, if any ("In-Kind Consideration") provided that any deficiencies in the Cash Consideration will be set off with additional Redeemed Shares and any deficiencies in the In-Kind Consideration will be set off with additional cash.

5.16. Changes in allowances and provision

Item	06/30/2018	Additions	Uses and reversals	Currency conversion difference	09/30/2018
DEDUCTED FROM ASSETS					
Allowance for impairment of trade debtors	(3,212,170)	(4,201)	77,331	483,065	(2,655,975)
Allowance for impairment of related parties	(23,126)	(21,358)	10,216	12,022	(22,246)
Allowance for obsolescence	(770,742)	(213,534)	-	136,952	(847,324)
Total deducted from assets	(4,006,038)	(239,093)	87,547	632,039	(3,525,545)
INCLUDED IN LIABILITIES					
Provisions for contingencies	(845,486)	-	132,863	253,749	(458,874)
Total included in liabilities	(845,486)	-	132,863	253,749	(458,874)
Total	**(4,851,524)**	**(239,093)**	**220,410**	**885,788**	**(3,984,419)**

Item	06/30/2017	Additions	Uses and reversals	Currency conversion difference	09/30/2017
DEDUCTED FROM ASSETS					
Allowance for impairment of trade debtors	(2,873,688)	(382,091)	540	(294,166)	(3,549,405)
Allowance for impairment of related parties	(205,960)	-	-	(8,405)	(214,365)
Allowance for obsolescence	(707,105)	(19,923)	213,216	41,180	(472,632)
Total deducted from assets	(3,786,753)	(402,014)	213,756	(261,391)	(4,236,402)
INCLUDED IN LIABILITIES					
Provisions for contingencies	(1,415,290)	-	-	144,391	(1,270,899)
Total included in liabilities	(1,415,290)	-	-	144,391	(1,270,899)
Total	**(5,202,043)**	**(402,014)**	**213,756**	**(117,000)**	**(5,507,301)**

6. INFORMATION ABOUT COMPONENTS OF COMBINED STATEMENT OF COMPREHENSIVE INCOME

6.1. Revenue

	09/30/2018	09/30/2017
Sale of goods	29,271,169	33,707,643
Rendering of services	8,940	24,683
Royalties	325,636	127,223
	29,605,745	33,859,549

Transactions of sales of goods and services with joint ventures and with shareholders and other related parties are reported in Note 12.

6.2. Cost of sales

Item	09/30/2018	09/30/2017
Inventory as of the beginning of the period	19,366,001	31,338,034
Adjustment of opening net book amount for the application of IAS 29	4,273,416	-
Purchases of the period	20,950,020	23,651,795
Production costs	2,094,206	2,794,113
Currency conversion difference	(7,094,698)	(1,298,391)
Subtotal	39,588,945	56,485,551
Inventory as of the end of the period	(25,089,935)	(36,473,918)
Cost of sales	**14,499,010**	**20,011,633**

6.3. R&D classified by nature

Item	Research and development expenses 09/30/2018	Research and development expenses 09/30/2017
Amortization intangible assets	212,895	197,940
Import and export expenses	2,230	4,228
Depreciation property, plant and equipment	40,326	118,181
Freight and haulage	-	255
Employee benefits and social securities	387,965	371,777
Taxes	1,139	1,406
Maintenance	6,076	13,174
Energy and fuel	15,375	11,410
Supplies and materials	341,186	109,232
Mobility and travel	9,806	29,979
Stock options based incentive	3,804	10,540
Professional fees and outsourced services	16,456	34,948
Office supplies	7,163	15,170
Insurance	1,583	6,484
Miscellaneous	2,488	13,650
Total	1,048,492	938,374

	09/30/2018	09/30/2017
R&D Capitalized (Note 5.7)	283,752	111,124
R&D profit and loss	1,048,492	938,374
Total	1,332,244	1,049,498
% of total revenue	4.50%	3.10%

6.4. Expenses classified by nature and function

Item	Production costs	Selling, general and administrative expenses	Total 09/30/2018
Amortization intangible assets	-	204,976	204,976
Analysis and storage	125,659	40,439	166,098
Commissions and royalties	298,478	50,462	348,940
Bank expenses and commissions	-	6,444	6,444
Import and export expenses	9,566	245,859	255,425
Depreciation property, plant and equipment	245,762	118,196	363,958
Impairment of receivables	-	(9,067)	(9,067)
Freight and haulage	25,448	334,319	359,767
Employee benefits and social securities	890,475	2,741,959	3,632,434
Maintenance	78,896	60,533	139,429
Energy and fuel	74,815	117,615	192,430
Supplies and materials	56,927	49,352	106,279
Mobility and travel	7,570	281,930	289,500
Publicity and advertising	-	296,226	296,226
Contingencies	-	(5,047)	(5,047)
Professional fees and outsourced services	-	333,472	333,472
Professional fees related parties	-	122,764	122,764
Office supplies	1,672	62,023	63,695
Insurance	14,571	95,953	110,524
System expenses	-	108,476	108,476
Obsolescence	213,534	-	213,534
Taxes	4,595	732,009	736,604
Miscellaneous	46,238	91,592	137,830
Total	2,094,206	6,080,485	8,174,691

Item	Production costs	Selling, general and administrative expenses	Total 09/30/2017
Amortization intangible assets	-	379,093	379,093
Analysis and storage	26,253	6,225	32,478
Commissions and royalties	49,108	113,516	162,624
Bank expenses and commissions	-	5,912	5,912
Import and export expenses	24,683	365,733	390,416
Depreciation property, plant and equipment	278,779	237,471	516,250
Impairment of receivables	-	381,551	381,551
Freight and haulage	54,137	414,916	469,053
Employee benefits and social securities	1,920,490	3,506,740	5,427,230
Maintenance	250,709	150,103	400,812
Energy and fuel	47,380	128,477	175,857
Supplies and materials	47,763	2,078	49,841
Mobility and travel	8,793	203,943	212,736
Publicity and advertising	-	586,814	586,814
Professional fees and outsourced services	-	394,220	394,220
Professional fees related parties	-	133,755	133,755
Office supplies	9,230	170,788	180,018
Insurance	26,206	139,638	165,844
System expenses	-	75,010	75,010
Obsolescence	19,923	-	19,923
Taxes	6,789	825,666	832,455
Miscellaneous	23,870	173,559	197,429
Total	2,794,113	8,395,208	11,189,321

6.5. Finance income

	09/30/2018	09/30/2017
Exchange differences	11,934,458	1,140,487
Interest generated by assets	61,214	126,181
Interest generated by assets related parties	-	12,366
Others finance income	23,447	-
Net gain of inflation effects on the monetary items	397,369	-
Changes in fair value of financial assets or liabilities and other financial results	47,829	47,680
	12,464,317	1,326,714

6.6. Finance costs

	09/30/2018	09/30/2017
Exchange differences	(21,471,990)	(2,609,834)
Interest generated by liabilities related parties	(7,054)	-
Interest generated by liabilities	(3,731,484)	(3,675,693)
Financial commissions	(296,405)	(481,308)
Others finance cost	(674,558)	-
Changes in fair value of financial assets or liabilities and other financial results	(18,480)	-
	(26,199,971)	(6,766,835)

7. INFORMATION ABOUT COMBINED COMPONENTS OF EQUITY

7.1. Parent company investment

The Group has recognized the contribution made by Bioceres into the combined entity as Parent company investment as follows:

	09/30/2018	09/30/2017
Intangible contributed	230,853	-
Rizobacter acquisition consideration	(8,144,018)	-
	(7,913,165)	-

7.2. Non-controlling interests

There were no dividends paid to non-controlling interest (NCI) in the period ended September 30, 2018, and 2017 after the acquisition of Rizobacter.

8. CASH FLOW INFORMATION

Significant non-cash transactions related to investing and financing activities are as follows:

	09/30/2018	09/30/2017
Financing activities		
Parent company investment	(7,913,165)	-
	(7,913,165)	**-**

9. JOINT VENTURES

Investments in joint ventures and related companies:

	09/30/2018	06/30/2018
Assets		
Semya S.A.	3,003,796	2,972,239
Synertech	19,488,191	16,099,816
Indrasa Biotecnología S.A.	17,658	-
	22,509,645	19,072,055

	09/30/2018	06/30/2018
Liabilities		
Trigall Genetics	2,086,376	2,012,298
	2,086,376	2,012,298

Changes in join ventures investmens:

	09/30/2018	09/30/2017
As of the beginning of the period	17,059,757	30,580,943
Monetary contributions	116,230	-
Adjustment for loss of control Indrasa	10,591	-
Revaluation of property, plant and equipment	562,268	-
Adjustment of opening net book amount for the application of IAS 29	8,328,794	-
Foreign currency translation	(5,734,527)	(1,264,283)
Share of profit or loss	80,156	55,117
As of the end of the period	20,423,269	29,371,777

Share of profit or loss of joint ventures:

	09/30/2018	09/30/2017
Trigall	(74,079)	(199,403)
Semya	(27,083)	(2,860)
Synertech	174,251	257,380
Indrasa	7,067	-
	80,156	55,117

10. SEGMENT INFORMATION

The Group is organized into three main operating segments:

- **Seed and integrated products**

The seed and integrated products segment focuses mainly on the development and commercialization of seed technologies and products that increase yield per hectare, with a focus on the provision of seed technologies and integrated crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics, to improve nutritional value and other benefits. The segment focuses on the commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments—in order to increase crop productivity and create value for customers. While each component can increase yield independently, through an integrated technology strategy the segment offers biotechnological events, germplasm and treatments for seeds that complement and integrate with each other to generate higher yields in crops.
Currently the segment generates revenue from ordinary activities through the sale of seeds, integrated packs, royalties and licenses charged to third parties, among others.

- **Crop protection**

The crop protection segment mainly includes the development, production and marketing of adjuvants, insecticides and fungicides. The adjuvants are used in mixtures to facilitate greater efficiency of the products to be applied (such as fertilizers and agrochemicals). Insecticides and fungicides can significantly reduce disease or insect problems during the germination period.

The segment currently generates revenue from ordinary activities through the sale of adjuvants, insecticides, fungicides and baits, among others.

- **Crop nutrition**

The crop nutrition segment focuses mainly on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers including biofertilizers and microgranulated fertilizers that optimize the productivity and yield of the crops.

Currently the segment generates income from ordinary activities through the sale of inoculants, bio-inductors, biological fertilizers and microgranulated fertilizers, among others

The measurement principles for the Group’s segment reporting structure are based on the IFRS principles adopted in the Combined financial statements. Revenue generated by products and services exchanged between segments and entities within the Group are calculated on the basis of market prices.

The following tables present information with respect to the Group´s reporting segments:

Period ended September 30, 2018	Seed and integrated products	Crop protection	Crop nutrition	Combined
Revenues				
Sale of goods	6,196,593	14,673,792	8,400,784	29,271,169
Rendering of services	8,940			8,940
Royalties	325,636			325,636
Government grants				
Grants	6,479			6,479
Total revenue	6,537,648	14,673,792	8,400,784	29,612,224
Cost of sales	(2,190,036)	(7,349,496)	(4,959,478)	(14,499,010)
Gross margin per segment	4,347,612	7,324,296	3,441,306	15,113,214
%	67%	50%	41%	51%

Period ended September 30, 2017	Seed and integrated products	Crop protection	Crop nutrition	Combined
Revenues				
Sale of goods	7,370,812	16,795,948	9,540,883	33,707,643
Rendering of services	24,683			24,683
Royalties	127,223			127,223
Government grants				
Grants	14,612			14,612
Total revenue	7,537,330	16,795,948	9,540,883	33,874,161
Cost of sales	(2,462,759)	(10,038,912)	(7,509,962)	(20,011,633)
Gross margin per segment	5,074,571	6,757,036	2,030,921	13,862,528
%	67%	40%	21%	41%

	09/30/2018	09/30/2017
Seed and integrated products	**6,537,648**	**7,537,330**
Seeds, royalties & licenses	855,316	1,021,347
Packs	5,682,332	6,515,983
Crop protection	**14,673,792**	**16,795,948**
Adjuvants	6,398,032	7,993,798
Insecticides & fungicides	2,479,124	2,409,728
Other	5,796,636	6,392,422
Crop nutrition	**8,400,784**	**9,540,883**
Inoculants	3,195,459	6,306,921
Fertilizers	5,205,325	3,233,962
Total revenue	**29,612,224**	**33,874,161**

11. FINANCIAL INSTRUMENTS – RISK MANAGEMENT

The following tables show additional information required under IFRS 7 on the financial assets and liabilities recorded as of September 30, 2018 and June 30, 2018.

	Amortized cost		Mandatorily measured at fair value through profit or loss	
Financial asset	**09/30/2018**	**06/30/2018**	**09/30/2018**	**06/30/2018**
Cash and cash equivalents	3,255,981	2,215,103	-	-
Other financial assets	4,838,642	4,781,679	8,766	12,526
Trade receivables	52,806,907	52,888,427	-	-
Other receivables (*)	7,454,378	7,732,901	-	-
Total	**68,355,908**	**67,618,110**	**8,766**	**12,526**

(*) Advances expenses and tax balances are not included.

	Amortized cost		Mandatorily measured at fair value through profit or loss	
Financial liability	**09/30/2018**	**06/30/2018**	**09/30/2018**	**06/30/2018**
Trade Payables and other payables	37,881,886	27,708,830	-	-
Borrowings	92,939,227	91,017,133	-	-
Financed payment - Acquisition of business	23,318,982	22,874,609	-	-
Total	**154,140,095**	**141,600,572**	**-**	**-**

11.1. Financial instruments measured at fair value

Measurement at fair value at 09/30/2018	**Level 1**	**Level 2**	**Level 3**
Financial assets at fair value			
Other financial assets	8,766	-	-

Measurement at fair value at 06/30/2018	**Level 1**	**Level 2**	**Level 3**
Financial assets at fair value			
Other financial assets	12,526	-	-

Estimation of fair value

The fair value of marketable securities is calculated using the market approach using quoted prices in active markets for identical assets (Level 1 of the fair value hierarchy).

The Group's financial liabilities, which were not traded in an active market were determined using valuation techniques that maximize the use of available market information, and thus rely as little as possible on specific estimates of the entity. The rates applicable to similar loans in the market (Level 2 of the fair value hierarchy) were compared.
The Group's policy is to recognize transfers between different categories of the fair value hierarchy at the time they occur or when there are changes in the circumstances that cause the transfer.

There were no transfers between levels of the fair value hierarchy. There were no changes in economic or business circumstances affecting fair value.

11.2. Financial instruments not measured at fair value

The financial instruments not measured at fair value include cash and cash equivalents, trade accounts receivable, other accounts receivable, trade payables and other debts, borrowings, financed payments and instruments with a purchase option (Note 5.15).

The carrying value of financial instruments not measured at fair value does not differ significantly from their fair value, except for borrowings (Note 5.10).

Management estimates that the carrying value of the financial instruments measured at amortized cost approximates their fair value.

12. SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS

During the period ended September 30, 2018 and 2017 the transactions between the Group and related parties, and the related balances owed by and to them, are as follows:

Party	Transaction type	09/30/2018	09/30/2017
Joint ventures	R&D sales and services	33,304	-
Joint ventures	Purchases of goods and services	(4,075,892)	(4,199,798)
Joint ventures	Equity contributions	116,230	-
Joint ventures	Loans granted	-	46,242
Key management personnel	Salaries, social security benefits and other benefits	(595,921)	(845,510)
Shareholders and other related parties	Sales of goods and services	166,551	275,902
Shareholders and other related parties	Interest gain	-	12,366
Shareholders and other related parties	Interest lost	(7,054)	-
Shareholders and other related parties	Purchases of goods and services	(172,285)	(460,045)
Parent company	Sales of goods and services	-	2,285
Parent company	Purchases of goods and services	(22,140)	-
Total		(4,557,207)	(5,168,558)

		Amounts receivable from related parties	
Party	**Transaction type**	**09/30/2018**	**06/30/2018**
Parent company	Trade receivables	401,017	361,606
Parent company	Other accounts receivable	322,475	103,251
Shareholders and other related parties	Trade receivables	940,126	571,216
Shareholders and other related parties	Allowance for impairment	(22,246)	(23,126)
Shareholders and other related parties	Other accounts receivable	3,656	119,677
Joint ventures	Trade receivables	174,441	209,039
Joint ventures	Other accounts receivable	5,968,694	6,299,467
Total		7,788,163	7,641,130

		Amounts payable to related parties	
Party	**Transaction type**	**09/30/2018**	**06/30/2018**
Parent company	Loans payables	(5,221,697)	(1,816,084)
Key management personnel	Salaries, social security benefits and other benefits	(51,574)	(1,556,035)
Shareholders and other related parties	Trade payables	(273,135)	(365,994)
Joint ventures	Trade payables	(7,825,308)	(3,493,113)
Total		(13,371,714)	(7,231,226)

13. KEY MANAGEMENT PERSONNEL COMPENSATION

The compensation of directors and other members of key management personnel, including social contributions and other benefits, was as follows for the period ended September 30, 2018, and 2017.

	09/30/2018	09/30/2017
Salaries, social security and other benefits	595,921	845,510
Total	**595,921**	**845,510**

The Group currently does not pay any compensation to any of its non-employee board members.

14. CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS

In order to guarantee the obligations assumed on the Syndicated loan (Note 5.10), Rizobacter signed a granted a pledge of a fixed term certificate constituted on September 10, 2018 for USD 4.3 million disclosed as “Restricted short-term deposit” in “Other financials assets” (Note 5.2).

There were no other significant changes to the contingencies, commitments and restrictions on the distribution of profits from the disclosed made in the Combined financial statement as of June 30, 2018, June 30, 2017, December 31, 2016, for the year ended June 30, 2018, for the six-month transition period ended June 30, 2017 and for the years ended December 31, 2016 and 2015.

15. EVENTS OCCURRING AFTER THE REPORTING PERIOD

Subsequent to September 30, 2018, there have been no other situations or circumstances that may require significant adjustments or further disclosure in these Unaudited Interim condensed combined financial statements that were not mencionad above.